ClinicalTrials.gg
CompletedNCT01506882Updated Dec 31, 2015Results posted

An Open Label Study of Levetiracetam Monotherapy in Patients With Newly Diagnosed Focal Epilepsy

A Phase 3 interventional study of Levetiracetam (LEV) in Epilepsy and Partial Onset Seizures, sponsored by UCB Japan Co. Ltd.. Completed at 27 sites in Japan. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2015-12-31.

Sponsored by UCB Japan Co. Ltd. (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies testing levetiracetam in Epilepsy — 4 open to participants now, 4 under way, 2 of them phase 3. Levetiracetam · Epilepsy.

Enrollment
33rd of 60
71 · median 94
Started
2011
with 4 others
Phase 3
28 of 60
2 open now
Registered
46th of 60
by date
Lead sponsor
7 of 60
UCB Japan Co. Ltd.

Among the 60 studies testing levetiracetam in Epilepsy, this one is the 33rd largest by enrollment, is one of 5 that started in 2011, is one of 28 in phase 3, and was the 46th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

4 of the 60 studies testing levetiracetam in Epilepsy are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About levetiracetam

Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing levetiracetam in Epilepsy, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of Levetiracetam (LEV) used as monotherapy, with efficacy measured as 6-month seizure freedom at the last evaluated dose in the LEV 1000 mg/day to 2000 mg/day group, in newly or recently diagnosed epilepsy subjects.

03

Conditions studied

  • Epilepsy
  • Partial Onset Seizures

Browse trials for

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is male or female and aged ≥ 16 years at Visit 1
  • Subjects with newly or recently diagnosed Epilepsy having experienced unprovoked Partial Seizures (IA, IB, IC), that are classifiable according to the International League Against Epilepsy (ILAE) classification of Epileptic Seizures
  • Subjects with at least 2 unprovoked seizures separated by a minimum of 48 hours in the year prior to Visit 1, of which, at least 1 unprovoked seizure occurred in the 3 months prior to Visit 1
  • Minimum body weight of 40 kg at Visit 1

Exclusion criteria

Exclusion Criteria:

  • Subject has a history or presence of seizure types other than partial (IA, IB, IC)
  • Subject has an experience of any type of brain surgery in the consecutive 2 years prior to Visit 1
  • Subject has a history or presence of known Pseudo-Seizures
  • Subject has been treated for Epilepsy with any Antiepileptic Drug (AED) within the 6 months prior to Visit 1. However, acute and sub-acute seizure treatments are accepted for a maximum use of 2 weeks, if the treatments are stopped for the week prior to Visit 1
  • Subject has a known acute or chronic illness, such as but not restricted to: cardiac, renal, hepatic dysfunction, endocrinological, or psychiatric illness, and that may impair reliable participation in the study or necessitate the use of medication not allowed by the protocol
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    Levetiracetam 1000 mg/day to 2000 mg/day group

    Subjects in the LEV 1000 mg/day to 2000 mg/day group receive the initial dose of LEV 1000 mg/day for the 1- week Stabilization Period and enter the Evaluation Period. Unless a seizure occurs during the Evaluation Period, the subjects will continue LEV 1000 mg/day for 26 weeks. If a seizure occurs during the Evaluation Period, the dose will be increased to 2000 mg/day and a restart of stabilization on LEV 2000 mg/day for 1 week is required prior to restarting the 26-weeks Evaluation Period on LEV 2000 mg/day. The LEV dose could be decreased as a fallback option at the investigator's discretion, if the subject did not tolerate the LEV dosage, as evidenced by the development of an AE. The fallback option was permitted to be performed once for subjects on LEV 2000 mg/day at any time during the restarted Stabilization Period (SP), restarted Evaluation Period (EP), or Maintenance Period (MP), as well as for subjects on LEV 3000 mg/day at any time during the SP, EP, or MP.

    Drug: Levetiracetam (LEV)

  • Experimental
    Levetiracetam 3000 mg/day group

    Unless a seizure occurs, the subjects in this arm will continue LEV 3000 mg/day for 26 weeks. Subjects in the LEV 3000 mg/day group undergo a 4-week Up-Titration Period prior to the 1-week Stabilization Period. They receive 1000 mg/day for 2 weeks and 2000 mg/day for 2 weeks during the Up-Titration Period and LEV 3000 mg/day for 1 week during the Stabilization Period. The LEV dose could be decreased as a fallback option at the investigator's discretion, if the subject did not tolerate the LEV dosage, as evidenced by the development of an AE. The fallback option was permitted to be performed once for subjects on LEV 2000 mg/day at any time during the restarted Stabilization Period (SP), restarted Evaluation Period (EP), or Maintenance Period (MP), as well as for subjects on LEV 3000 mg/day at any time during the SP, EP, or MP.

    Drug: Levetiracetam (LEV)

Interventions

  • * Active Substance: Levetiracetam * Pharmaceutical Form: Film-coated tablet * Concentration: LEV 250 mg, LEV 500 mg * Frequency: Twice daily * Route of Administration: Oral use

    Also known as: Keppra, E Keppra

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group Who Are Seizure Free for 26 Consecutive Weeks of Treatment During the Evaluation Period

    A subject was considered seizure free, if no seizure occurred during the 6 consecutive months (26 weeks) in the Evaluation Period. If one of the following occurred, the subject was not considered seizure free: * A documented seizure during 6 consecutive months of the Evaluation Analysis Period * Subject discontinued the study prematurely during the Evaluation Analysis Period * Missing Seizure Count Case Report Forms (CRFs) prior to completing the Evaluation Analysis Period.

    Time frame: From the end of the 1-week Stabilization Period over the 26-weeks Evaluation Period

Secondary outcomes

  1. Percentage of Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group Who Are Seizure Free for 52 Consecutive Weeks of Treatment During the Evaluation Period and the Maintenance Period

    Subjects who complete the 26-weeks Evaluation Period without having a seizure will continue receiving the same dose of LEV as in the Evaluation Period during the 26-weeks Maintenance Period unless a seizure occurs.

    Time frame: From entry in the 26-weeks Evaluation Period to the end of the 26-weeks Maintenance Period

  2. Percentage of Subjects in the Levetiracetam (LEV) 3000 mg/Day Group Who Are Seizure Free for 26 Consecutive Weeks of Treatment During the Evaluation Period

    A subject was considered seizure free, if no seizure occurred during the 6 consecutive months (26 weeks) in the Evaluation Period. If one of the following occurred, the subject was not considered seizure free: * A documented seizure during 6 consecutive months of the Evaluation Analysis Period * Subject discontinued the study prematurely during the Evaluation Analysis Period * Missing Seizure Count Case Report Forms (CRFs) prior to completing the Evaluation Analysis Period.

    Time frame: From the end of the 1-week Stabilization Period over the 26-weeks Evaluation Period

  3. Percentage of Subjects in the Levetiracetam (LEV) 3000 mg/Day Group Who Are Seizure Free for 52 Consecutive Weeks of Treatment During the Evaluation Period and the Maintenance Period

    Subjects who complete the 26-weeks Evaluation Period without having a seizure will continue receiving LEV 3000 mg/day during the 26-weeks Maintenance Period unless a seizure occurs.

    Time frame: From entry in the 26-weeks Evaluation Period to the end of the 26-weeks Maintenance Period

  4. Time to First Seizure at the Last Evaluated Dose in Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group

    Time was measured from first day of last evaluated dose. Seizures during Stabilization were not considered. The Median time to first seizure will be estimated from the Kaplan-Meier curve.

    Time frame: During Evaluation, Maintenance and Safety Follow Up Period after 1-week Stabilization Period, assessed up to 1 year

  5. Time to Withdrawal at the Last Evaluated Dose in Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group

    Median time to withdrawal will be estimated from the Kaplan-Meier curve.

    Time frame: During 1-week Stabilization Period, Evaluation, Maintenance and Safety Follow Up Period, assessed up to 1 year

  6. Time to First Seizure in Subjects in the Levetiracetam (LEV) 3000 mg/Day Group

    Time was measured from first day of last evaluated dose. Seizures during Stabilization were not considered. The Median time to first seizure will be estimated from the Kaplan-Meier curve.

    Time frame: During Evaluation, Maintenance and Safety Follow Up Period after 1-week Stabilization Period, assessed up to 1 year

  7. Time to Withdrawal in Subjects in the Levetiracetam (LEV) 3000 mg/Day Group

    Median time to withdrawal will be estimated from the Kaplan-Meier curve.

    Time frame: During 1-week Stabilization Period, Evaluation, Maintenance and Safety Follow Up Period, assessed up to 1 year

07

Results

Posted Oct 13, 2014

Participant flow

This multicenter study started to enroll subjects in December 2011 in order to end up with 27 centers with enrolled subjects in Japan.

Participant flow — Overall Study
MilestoneLevetiracetam 1000 mg/Day to 2000 mg/Day GroupLevetiracetam 3000 mg/Day Group
Started6110
Completed393
Not completed227
Withdrew: Lack of efficacy43
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject93
Withdrew: Sae, non-fatal20
Withdrew: Ae, non-serious non-fatal31
Withdrew: Sae,non-fatal+ae,non-serious non-fatal10
Withdrew: Other reason20

Outcome measures

PrimaryPercentage of Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group Who Are Seizure Free for 26 Consecutive Weeks of Treatment During the Evaluation Period

A subject was considered seizure free, if no seizure occurred during the 6 consecutive months (26 weeks) in the Evaluation Period. If one of the following occurred, the subject was not considered seizure free: * A documented seizure during 6 consecutive months of the Evaluation Analysis Period * Subject discontinued the study prematurely during the Evaluation Analysis Period * Missing Seizure Count Case Report Forms (CRFs) prior to completing the Evaluation Analysis Period.

Time frame:
From the end of the 1-week Stabilization Period over the 26-weeks Evaluation Period
Reported as:
Number · percentage of participants
Percentage of Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group Who Are Seizure Free for 26 Consecutive Weeks of Treatment During the Evaluation Period
percentage of participantsLevetiracetam 1000 mg/Day to 2000 mg/Day Group
Percentage of Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group Who Are Seizure Free for 26 Consecutive Weeks of Treatment During the Evaluation Period73.8 (60.9 to 84.2)
Statistical analysis
  • Levetiracetam 1000 mg/Day to 2000 mg/Day Group · Percent: 73.8 · 95% CI 60.9 to 84.2
SecondaryPercentage of Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group Who Are Seizure Free for 52 Consecutive Weeks of Treatment During the Evaluation Period and the Maintenance Period

Subjects who complete the 26-weeks Evaluation Period without having a seizure will continue receiving the same dose of LEV as in the Evaluation Period during the 26-weeks Maintenance Period unless a seizure occurs.

Time frame:
From entry in the 26-weeks Evaluation Period to the end of the 26-weeks Maintenance Period
Reported as:
Number · percentage of participants
Percentage of Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group Who Are Seizure Free for 52 Consecutive Weeks of Treatment During the Evaluation Period and the Maintenance Period
percentage of participantsFull Analysis Set (LEV 1000 mg/Day to 2000 mg/Day Group)
Percentage of Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group Who Are Seizure Free for 52 Consecutive Weeks of Treatment During the Evaluation Period and the Maintenance Period59.0 (45.7 to 71.4)
SecondaryPercentage of Subjects in the Levetiracetam (LEV) 3000 mg/Day Group Who Are Seizure Free for 26 Consecutive Weeks of Treatment During the Evaluation Period

A subject was considered seizure free, if no seizure occurred during the 6 consecutive months (26 weeks) in the Evaluation Period. If one of the following occurred, the subject was not considered seizure free: * A documented seizure during 6 consecutive months of the Evaluation Analysis Period * Subject discontinued the study prematurely during the Evaluation Analysis Period * Missing Seizure Count Case Report Forms (CRFs) prior to completing the Evaluation Analysis Period.

Time frame:
From the end of the 1-week Stabilization Period over the 26-weeks Evaluation Period
Reported as:
Number · percentage of participants
Percentage of Subjects in the Levetiracetam (LEV) 3000 mg/Day Group Who Are Seizure Free for 26 Consecutive Weeks of Treatment During the Evaluation Period
percentage of participantsLevetiracetam 3000 mg/Day Group
Percentage of Subjects in the Levetiracetam (LEV) 3000 mg/Day Group Who Are Seizure Free for 26 Consecutive Weeks of Treatment During the Evaluation Period22.2 (2.8 to 60.0)
SecondaryPercentage of Subjects in the Levetiracetam (LEV) 3000 mg/Day Group Who Are Seizure Free for 52 Consecutive Weeks of Treatment During the Evaluation Period and the Maintenance Period

Subjects who complete the 26-weeks Evaluation Period without having a seizure will continue receiving LEV 3000 mg/day during the 26-weeks Maintenance Period unless a seizure occurs.

Time frame:
From entry in the 26-weeks Evaluation Period to the end of the 26-weeks Maintenance Period
Reported as:
Number · percentage of participants
Percentage of Subjects in the Levetiracetam (LEV) 3000 mg/Day Group Who Are Seizure Free for 52 Consecutive Weeks of Treatment During the Evaluation Period and the Maintenance Period
percentage of participantsFull Analysis Set (LEV 3000 mg/Day Group)
Percentage of Subjects in the Levetiracetam (LEV) 3000 mg/Day Group Who Are Seizure Free for 52 Consecutive Weeks of Treatment During the Evaluation Period and the Maintenance Period11.1 (0.3 to 48.2)
SecondaryTime to First Seizure at the Last Evaluated Dose in Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group

Time was measured from first day of last evaluated dose. Seizures during Stabilization were not considered. The Median time to first seizure will be estimated from the Kaplan-Meier curve.

Time frame:
During Evaluation, Maintenance and Safety Follow Up Period after 1-week Stabilization Period, assessed up to 1 year
Reported as:
Median · days
Time to First Seizure at the Last Evaluated Dose in Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group
daysFull Analysis Set (LEV 1000 mg/Day to 2000 mg/Day Group)
Time to First Seizure at the Last Evaluated Dose in Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day GroupNA (359 to NA)
SecondaryTime to Withdrawal at the Last Evaluated Dose in Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group

Median time to withdrawal will be estimated from the Kaplan-Meier curve.

Time frame:
During 1-week Stabilization Period, Evaluation, Maintenance and Safety Follow Up Period, assessed up to 1 year
Reported as:
Median · days
Time to Withdrawal at the Last Evaluated Dose in Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group
daysFull Analysis Set (LEV 1000 mg/Day to 2000 mg/Day Group)
Time to Withdrawal at the Last Evaluated Dose in Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day GroupNA (NA to NA)
SecondaryTime to First Seizure in Subjects in the Levetiracetam (LEV) 3000 mg/Day Group

Time was measured from first day of last evaluated dose. Seizures during Stabilization were not considered. The Median time to first seizure will be estimated from the Kaplan-Meier curve.

Time frame:
During Evaluation, Maintenance and Safety Follow Up Period after 1-week Stabilization Period, assessed up to 1 year
Reported as:
Median · days
Time to First Seizure in Subjects in the Levetiracetam (LEV) 3000 mg/Day Group
daysFull Analysis Set (LEV 3000 mg/Day Group)
Time to First Seizure in Subjects in the Levetiracetam (LEV) 3000 mg/Day Group106 (9 to NA)
SecondaryTime to Withdrawal in Subjects in the Levetiracetam (LEV) 3000 mg/Day Group

Median time to withdrawal will be estimated from the Kaplan-Meier curve.

Time frame:
During 1-week Stabilization Period, Evaluation, Maintenance and Safety Follow Up Period, assessed up to 1 year
Reported as:
Median · days
Time to Withdrawal in Subjects in the Levetiracetam (LEV) 3000 mg/Day Group
daysLevetiracetam 3000 mg/Day Group
Time to Withdrawal in Subjects in the Levetiracetam (LEV) 3000 mg/Day Group91 (21 to 197)

Adverse events

Collected over Treatment-emergent Adverse Events were collected from Screening (Week 0) over the Evaluation and Maintenance Period (Week 4 to Week 53) until the last Follow-up Visit or Withdrawal Visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Levetiracetam 1000 mg/Day to 2000 mg/Day Group—8/61 (13.1%)58/61 (95.1%)
Levetiracetam 3000 mg/Day Group—2/10 (20%)10/10 (100%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventLevetiracetam 1000 mg/Day to 2000 mg/Day GroupLevetiracetam 3000 mg/Day Group
EpilepsyNervous system disorders0/611/10
Meniscus removalSurgical and medical procedures0/611/10
Status epilepticusNervous system disorders3/610/10
Postictal stateNervous system disorders2/610/10
IrritabilityGeneral disorders1/610/10
Anaphylactic reactionImmune system disorders1/610/10
CystitisInfections and infestations1/610/10
Kaposi's varicelliform eruptionInfections and infestations1/610/10
PyelonephritisInfections and infestations1/610/10
ConvulsionNervous system disorders1/610/10
Most frequent other events
Showing 10 of 47
Most frequent other events
EventLevetiracetam 1000 mg/Day to 2000 mg/Day GroupLevetiracetam 3000 mg/Day Group
NasopharyngitisInfections and infestations47/614/10
SomnolenceNervous system disorders25/612/10
DiarrhoeaGastrointestinal disorders8/612/10
Head injuryInjury, poisoning and procedural complications1/612/10
Weight increasedInvestigations2/612/10
MalaiseGeneral disorders12/610/10
HeadacheNervous system disorders10/611/10
DizzinessNervous system disorders8/611/10
InfluenzaInfections and infestations7/610/10
VertigoEar and labyrinth disorders0/611/10

Baseline characteristics

Baseline Characteristics refer to the Safety Set (SS). SS consists of all subjects in the Enrolled Set, who received at least 1 dose of the Investigational Medicinal Product (IMP).

Age, Categorical
Age, Categorical(Participants)Levetiracetam 1000 mg/Day to 2000 mg/Day GroupLevetiracetam 3000 mg/Day GroupTotal Title
<=18 years10111
Between 18 and 65 years45853
>=65 years617
Age, Continuous
Age, Continuous(years)Levetiracetam 1000 mg/Day to 2000 mg/Day GroupLevetiracetam 3000 mg/Day GroupTotal Title
Mean36.5 ± 18.037.0 ± 18.636.5 ± 17.9
Sex: Female, Male
Sex: Female, Male(Participants)Levetiracetam 1000 mg/Day to 2000 mg/Day GroupLevetiracetam 3000 mg/Day GroupTotal Title
Female34438
Male27633
Region of Enrollment
Region of Enrollment(participants)Levetiracetam 1000 mg/Day to 2000 mg/Day GroupLevetiracetam 3000 mg/Day GroupTotal Title
Japan611071
Weight
Weight(kilogram (kg))Levetiracetam 1000 mg/Day to 2000 mg/Day GroupLevetiracetam 3000 mg/Day GroupTotal Title
Mean58.98 ± 12.3062.58 ± 15.1159.48 ± 12.67
Height
Height(centimeter (cm))Levetiracetam 1000 mg/Day to 2000 mg/Day GroupLevetiracetam 3000 mg/Day GroupTotal Title
Mean161.96 ± 8.77166.07 ± 10.21162.54 ± 9.02
08

Study locations

27 sites
  • 19
    Aomori, Japan
  • 33
    Asaka, Japan
  • 21
    Daito, Japan
  • 12
    Fujisawa, Japan
  • 14
    Hamamatsu, Japan
  • 11
    Himeji, Japan
  • 30
    Hirosaki, Japan
  • 8
    Kagoshima, Japan
  • 20
    Kamakura, Japan
  • 17
    Kawasaki, Japan
  • 3
    Kitakyusyu, Japan
  • 26
    Kodaira, Japan
  • 9
    Kokubunji, Japan
  • 32
    Kyoto, Japan
  • 25
    Miyakonojo, Japan
  • 5
    Nagoya Aichi, Japan
  • 4
    Nara, Japan
  • 22
    Okayama, Japan
  • 24
    Osakasayama, Japan
  • 15
    Osaka, Japan
  • 27
    Osaka, Japan
  • 13
    Saitama, Japan
  • 1
    Sakai, Japan
  • 29
    Sapporo, Japan
  • 2
    Toyonaka, Japan
  • 7
    Ube, Japan
  • 18
    Yamagata, Japan
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Oct 2013 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2012
First posted
Jan 10, 2012
Start
Dec 2011
Primary completionActual
Oct 2013
CompletionActual
Apr 2015
Results first posted
Oct 13, 2014
Last update
Dec 31, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01506882
Lead sponsor
UCB Japan Co. Ltd.
Responsible party
Sponsor
First posted
Jan 10, 2012
Start date
Dec 2011
Primary completion
Oct 2013
Completion
Apr 2015
Results posted
Oct 13, 2014
Last update
Dec 31, 2015

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion